MedImmune
Company
Turkey Day Workers Lead Fight Against H1N1...know, but the front line in the fight against the Swine Flu pandemic is inside a plain looking warehouse in Northeast Philadelphia. Home to MedImmune, a division of Astra Zeneca, workers there produce every single dose of swine flu mist... In this article: E mail, MedImmune, and Astra Zeneca |
-
Medical News Today | 3 days ago
Why Some Vaccines May Require A Booster
...sinus and bronchitis vaccine. He has also received financial support for his research from vaccine companies including GlaxoSmithKline, MedImmune, Sanofipasteur and Wyeth (now Pfizer). Rochester General Health System (RGHS) has been...
In this article: Meningitis, Cervical cancer, Diphtheria, Tetanus, Medical advice, Pediatrics, Haemophilus influenzae type b, and American Academy of Pediatrics
-
Reuters | 3 days ago
Novartis opens new flu vaccine plant in US
...companies to make influenza immunizations for the U.S. market -- Novartis, Sanofi Aventis <SASY.PA>, CSL <CSL.AX>, AstraZeneca <AZN.L> unit MedImmune and GlaxoSmithKline <GSK.L>. In 2004, British authorities closed a contaminated plant...
In this article: Novartis, United States, HHS, Holly Springs, Sanofi, U.S. Centers for Disease Control and Prevention, U.S. House of Representatives, and European Union
-
Prime Newswire | 3 days ago
Micromet Enters Into Agreement With Lonza for the Manufacture of Blinatumomab
...with non-Hodgkin's lymphoma (NHL). Micromet controls the worldwide rights to develop and commercialize blinatumomab after it reacquired MedImmune's remaining rights to this product candidate on November 4, 2009. About BiTE Antibodies
In this article: Blinatumomab, Cancer, Bayer Schering Pharma, Antibodies, Acute lymphoblastic leukemia, Monoclonal antibodies, and Nycomed
-
Regulation, suspicion slow U.S. flu response: hearing
...live, attenuated influenza vaccines are likely to take many years and cost a great deal," said Ben Machielse of AstraZeneca unit MedImmune. "Manufacturers urgently need a way to discuss end-to-end product development plans with the...
In this article: United States, FDA, HHS, Influenza vaccine, House of Representatives, and Novartis
-
UPDATE 1-US officials defend swine flu vaccination plan
...doses by now. The problem was worsened because the first vaccine to be available was a nasal spray made by AstraZeneca <AZN.L> unit MedImmune that is not suitable for some of the most vulnerable groups but which is perfect for most...
In this article: HHS, Joseph Lieberman, U.S., Kathleen Sebelius, and Asthma
-
UPDATE 1-Novartis says lower H1N1 vaccine dose may suffice
...H1N1 vaccine from five makers who already produce seasonal flu vaccine -- GlaxoSmithKline Plc <GSK.L>, AstraZeneca Plc's <AZN.L> MedImmune unit, Novartis <NOVN.VX>, Sanofi-Aventis <SASY.PA>, and CSL Limited <CSL.AX>. (Reporting by Emma...
In this article: Novartis, FDA, U.S., CSL Limited, and Sanofi-Aventis
-
washingtonpost.com | November 16, 2009
HHS has not learned from H1N1 mistakes: senators
...to vaccinate. Some hospitals, for instance, did not want to use the first available vaccine, a nasal spray made by AstraZeneca unit MedImmune. But Collins and Lieberman said the message was too confusing. "This approach raises doubts...
In this article: HHS, Susan Collins, Joseph Lieberman, H1N1, Asthma, Vanderbilt University, AstraZeneca, and U.S. Centers for Disease Control and Prevention
-
PR Newswire: Health / Biotech | November 16, 2009
MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition
The title of her abstract is "The role of TAM receptor tyrosine kinases in B cell activation and differentiation." About MedImmune MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately...
In this article: Autoimmunity, Arthritis, University of North Carolina at Chapel Hill, Harvard Medical School, Boston University School of Medicine, and AstraZeneca PLC
-
Philly.com | November 15, 2009
Vaccine for swine flu scores a success
...that it weakens, or attenuates. Live virus is easier to grow than inactivated virus. The CDC gives MedImmune virus components, but the company makes its own seed. Ben Machielse, MedImmune's executive vice president of operations, said...
In this article: FLU, MedImmune Inc., FluMist, H1N1, AstraZeneca, Legal age, and Revenue
-
Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
...treatment of cancer, inflammation and autoimmune diseases, today announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune's rights to blinatumomab in North America, and to terminate the collaboration agreement signed...
In this article: Blinatumomab, Cancer, North America, Bayer Schering Pharma, Leukemia, Monoclonal antibodies, Nycomed, and Merck Serono
Trends
Loading...
More on MedImmune
Description from Wikipedia:
MedImmune, LLC, headquartered in Gaithersburg, Maryland, became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired, MedImmune has remained a Maryland-based biotechnology development enterprise. It produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for $1.06 billion of its $1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004.
FluMist was approved for children 2 and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market -- the millions of young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.
MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was FDA approved in 2007, and is now the form offered on the market.
MedImmune reported a 16.6 million loss in 2005, and a $3.8 million loss the previous year for $1.14 billion in revenue. On April 23, 2007 it was announced MedImmune and AstraZeneca entered into a definitive agreement under which AstraZeneca intends to acquire MedImmune in an all cash transaction at $58 per share, or about $15.2 billion.
In June 2007, the National Institutes of Health (NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal influenza vaccine candidate based on MedImmune's live, attenuated vaccine technology.
Explore everything named MedImmune...
